Search Results for: 19

ROCKVILLE, Md., Sept. 10, 2013 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, announced today that Jeffrey Riley, CEO, will present at the First Global Life Sciences Conference to be held on September 16-17, 2013 in Warsaw, Poland. Mr. Riley is scheduled to […]

ROCKVILLE, Md., June 19, 2013 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, announced today that Jeffrey Riley, CEO, will present at the 6th Annual OneMedForum New York Conference on Thursday, June 27, 2013 at The Metropolitan Club in New York

ROCKVILLE, Md., May 15, 2013 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, today reported financial results for the three months ended March 31, 2013 and summarized operational highlights. Operational Highlights Emphasis on C. difficile (C. diff) Infection Prevention (SYN-004) In the

ROCKVILLE, Md., April 19, 2013 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, reiterated that the Exclusive Channel Collaboration Agreement dated August 6, 2012 between the Company and Intrexon Corporation (Intrexon) remains in effect, as stated earlier today. This Exclusive Channel Collaboration

— Strengthening Infectious Disease Portfolio to Include C. difficile, Pertussis and Acinetobacter Targets — ROCKVILLE, Md., April 16, 2013 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, today reported financial results for the year ended December 31, 2012 and summarized recent operational

ROCKVILLE, Md., March 12, 2013 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for serious infections and diseases, announced today that its Chief Executive Officer, Jeffrey Riley, will present at the 25th Annual ROTH Conference being held on March 17-20, 2013 at the Ritz-Carlton, Laguna Niguel in Dana

— The University of Texas at Austin to Join in Pertussis Research Efforts — ROCKVILLE, Md. and SAN FRANCISCO, Dec. 20, 2012 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for serious infections and diseases, and Intrexon Corporation, a leading synthetic biology company that utilizes its proprietary technologies to provide

— Accelerating Development of Product Candidates to Address Serious Infectious Diseases — ROCKVILLE, Md., Nov. 14, 2012 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for serious infections and diseases, today reported financial results for the three and nine months ended September 30, 2012 and summarized operational highlights.

— Addition of Monoclonal Antibodies for Infectious Diseases Emphasizes Focus on Synthetic Biologics — ANN ARBOR, Mich., Aug. 14, 2012 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for unmet medical needs, today reported financial results for the three and six months ended June 30, 2012 and

— Preclinical and Clinical Programs Moving Forward — ANN ARBOR, Mich., May 15, 2012 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE Amex: SYN), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, today reported financial results for the three months ended March 31, 2012 and summarized operational highlights. Operational Highlights Management Team –